Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01271426
Recruitment Status : Completed
First Posted : January 6, 2011
Last Update Posted : January 6, 2011
Information provided by:
Nihon University

Brief Summary:
To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.

Condition or disease
Polypoidal Choroidal Vasculopathy

Study Type : Observational
Actual Enrollment : 74 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Association of Complement Factor H and ARMS2 Genotypes With Response of Polypoidal Choroidal Vasculopathy to Intravitreal Ranibizumab
Study Start Date : April 2008
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab
U.S. FDA Resources

Primary Outcome Measures :
  1. Association of Complement Factor H and ARMS2 Genotypes with Response of Polypoidal Choroidal Vasuculopathy to Intravitral Ranibizumab [ Time Frame: a month after injection ]

Biospecimen Retention:   Samples With DNA
white blood cell

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
outpatients in hospital

Inclusion Criteria:

  • Clinical diagnosis of Polypoidal choroidal vasculopathy
  • must have injection of Ranibizumab

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01271426

Surugadai Nihon university hospital
1-8-13 Kandasurugadai Chiyoda-ku, Tokyo, Japan, 101-8309
Sponsors and Collaborators
Nihon University Identifier: NCT01271426     History of Changes
Other Study ID Numbers: NihonU-1
First Posted: January 6, 2011    Key Record Dates
Last Update Posted: January 6, 2011
Last Verified: January 2011

Keywords provided by Nihon University:
Polypoidal Choroidal Vasculopathy

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents